- Conditions
- Stage IV Non-small Cell Lung Cancer
- Interventions
- Belinostat, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 4
- States / cities
- Huntsville, Alabama • Santa Monica, California • Boynton Beach, Florida + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 1,628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Overweight
- Interventions
- Dietary Supplements and TR90 Eating Plan, Placebo and Low Fat Eating Plan
- Dietary Supplement
- Lead sponsor
- Pharmanex
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Logan, Utah
- Conditions
- Hypertension, Portal
- Interventions
- SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles), SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma, Wilms' Tumor, Neuroblastoma
- Interventions
- ODSH
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Carotid Stenosis, Caloric Restriction
- Interventions
- ScandiShake
- Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
- Interventions
- VIA Disc NP, Sham
- Other
- Lead sponsor
- VIVEX Biologics, Inc.
- Industry
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- Napa, California • Santa Monica, California • Thornton, Colorado + 16 more
- Conditions
- Breast Cancer
- Interventions
- Breast Cancer Screening, Survey/Interview, Focus Group
- Diagnostic Test · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Osteosarcoma Recurrent, Ewing's Tumor Recurrent
- Interventions
- DFMO
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- Up to 39 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate Transdermal System (MTS), placebo patch
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Peritoneal Carcinomatosis
- Interventions
- Paclitaxel-loaded tumor penetrating microparticles
- Drug
- Lead sponsor
- Carlos Chan
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Alcohol Use Disorder
- Interventions
- 200mg Cannabidiol oral solution, 30mg Cannabidiol oral solution, Placebo
- Dietary Supplement
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Autonomic Dysregulation, Anxiety, Depression, Parent-Child Relations
- Interventions
- Parent-Child Interaction Therapy (PCIT)
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Jacksonville, Florida
- Conditions
- Freeman-Sheldon Syndrome, Arthrogryposis Distal Type 2A, Whistling Face Syndrome, Craniocarpotarsal Dysplasia, Craniocarpotarsal Dystrophy, Freeman-Sheldon Syndrome Variant, Sheldon-Hall Syndrome, Arthrogryposis Distal Type 2B, Gordon Syndrome, Arthrogryposis Distal Type 3, Arthrogryposis Distal Type 1, Arthrogryposis, Distal, Type 1A, Arthrogryposis Distal Type 1B, Arthrogryposis, Distal, Craniofacial Abnormalities, Arthrogryposis
- Interventions
- PTSD Checklist-Civilian (PCL-C), Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale (CES-D), Functional Enquiry (or Review of Systems) Form, Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire, FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI), Medical Records Review
- Other
- Lead sponsor
- Freeman-Sheldon Research Group, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Buckhannon, West Virginia
- Conditions
- Hepatitis C Virus, HCV Infection, Chronic HCV, Hepatitis C
- Interventions
- Naringenin
- Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
- Conditions
- Breast Cancer, HER-2 Positive Breast Cancer
- Interventions
- Resistant Potato Starch, Placebo control
- Dietary Supplement
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Allergic Conjunctivitis, Allergic Rhinitis
- Interventions
- Dose Level 1, Dose Level 2, Placebo
- Biological
- Lead sponsor
- Woodmont Pharmaceuticals, Inc.
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Heart Failure With Normal Ejection Fraction, Obesity
- Interventions
- Increasing daily unsaturated fatty acid consumption
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Lymphoma
- Interventions
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Biological · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 94
- States / cities
- Little Rock, Arkansas • Burbank, California • La Jolla, California + 63 more
- Conditions
- Heart Failure Patients
- Interventions
- Feasibility of wearing a Readiband to monitor Sleep and Fatigue
- Device
- Lead sponsor
- University of Massachusetts, Amherst
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Amherst, Massachusetts
- Conditions
- Cancer
- Interventions
- methotrexate, methylprednisolone, prednisone
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, Imaging biomarker analysis, Photon Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Graft-versus-host-disease (GVHD)
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Omaha, Nebraska • Cleveland, Ohio + 2 more
- Conditions
- Hearing Loss
- Interventions
- Not listed
- Lead sponsor
- Oticon Medical
- Industry
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia